Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 14/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.35 |
| ▸ | FKBP1B | P68106 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203330 | 0.91 | KCNH2 (0.36) | MTORKCNH2FKBP1AFKBP1BPRKDC | |
| SCHEMBL4212847 | 0.82 | KDM1A (0.32) | KCNH2 | |
| SCHEMBL3612945 | 0.82 | KCNH2 (0.36) | MTORKCNH2FKBP1AFKBP1BPRKDC | |
| Hydrochloric Acid SCHEMBL4367609 | 0.81 | KDM1A (0.32) | — | |
| SCHEMBL2821376 | 0.80 | MTOR (0.35) | MTORKCNH2 | |
| SCHEMBL2821119 | 0.76 | KCNH2 (0.64) | KCNH2TOP2A | |
| Hydrochloric Acid SCHEMBL3607827 | 0.76 | KCNH2 (0.38) | MTORKCNH2FKBP1AFKBP1BPRKDC | |
| Hydrochloric Acid SCHEMBL3611488 | 0.76 | KCNH2 (0.38) | MTORKCNH2FKBP1AFKBP1BPRKDC | |
| Hydrochloric Acid SCHEMBL3611995 | 0.76 | KCNH2 (0.37) | MTORKCNH2FKBP1AFKBP1BPRKDC | |
| SCHEMBL3611984 | 0.75 | TOP2A (0.35) | MTORKCNH2FKBP1AFKBP1BPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041145-B1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-20100004230-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004230-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | AADAC, AZI2, NNMT | MTOR 205/4885KCNH2 2592/4885FKBP1A 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.